Onconetix issued a press release detailing Q1 2026 operational and clinical progress at Proteomedix AG, including two new peer-reviewed publications on Proclarix and initiation of a U.S. validation study with Labcorp.
Key takeaways
Two peer-reviewed papers published: Schiess et al. in BMC Cancer (371 men cohort) showing Proclarix reduces overdiagnosis and biopsies better than %fPSA and ERSPC calculator.
Athanasiou et al. in Cancers demonstrating Proclarix prognostic value in predicting active surveillance to treatment transition (132 men cohort).
PRIME multi-center U.S. validation study initiated with Labcorp; first participants enrolled, targeting up to 500 men across ethnicities.
Nearly 100 Proclarix tests conducted in Q1 2026 UK screening initiative via patient organization.
Commercial expansion: collaboration partner identified in Turkey; ongoing efforts in additional European countries.